Los Angeles Capital Management LLC Has $1.43 Million Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Los Angeles Capital Management LLC decreased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 47.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,087 shares of the company’s stock after selling 69,843 shares during the period. Los Angeles Capital Management LLC owned about 0.16% of Pacira BioSciences worth $1,433,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Pacer Advisors Inc. grew its stake in shares of Pacira BioSciences by 129.4% during the third quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after purchasing an additional 2,799,434 shares during the last quarter. State Street Corp grew its stake in shares of Pacira BioSciences by 5.8% during the third quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after purchasing an additional 110,162 shares during the last quarter. Impax Asset Management Group plc grew its stake in shares of Pacira BioSciences by 14.8% during the fourth quarter. Impax Asset Management Group plc now owns 540,027 shares of the company’s stock valued at $10,174,000 after purchasing an additional 69,424 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Pacira BioSciences by 4.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 431,897 shares of the company’s stock valued at $6,500,000 after purchasing an additional 16,819 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Pacira BioSciences by 11.8% during the fourth quarter. Bank of New York Mellon Corp now owns 396,399 shares of the company’s stock valued at $7,468,000 after purchasing an additional 41,881 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on PCRX shares. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price target for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. HC Wainwright increased their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research note on Friday. Barclays raised their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday. Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Trading Down 5.2 %

Shares of NASDAQ PCRX opened at $24.05 on Friday. The company’s fifty day moving average is $23.16 and its 200-day moving average is $18.58. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -11.85 and a beta of 0.80. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.